Sunshine Provision Retained In Opioids Bill Compromise
Congressional negotiators knitting together US Senate and House versions of opioids legislation retained “sunshine” provision opposed by industry that would expand the types of health-care professionals for whom device and drug manufacturers must report to the federal Open Payments database.
You may also be interested in...
A provision to expand Sunshine Act industry reporting requirements for companies in the Senate-passed “Opioid Crisis Response Act” has caught criticism from the device sector, despite overall industry support for the legislation.
On this week’s podcast we talk about outgoing US FDA chief Stephen Hahn and the role he wants to play beyond 20 January, as an ex-commissioner. We also discuss the US enforcement landscape around COVID-19-related products and how it’s still taking shape.
The US Medicare agency issued on 12 January its final MCIT rule allowing instant reimbursement for FDA breakthrough devices – unless the incoming Biden administration blocks it.